Literature DB >> 17526842

Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis.

Dervla T Kenna1, Catherine J Doherty1, Juliet Foweraker2, Lisa Macaskill3, Victoria A Barcus1, John R W Govan1.   

Abstract

Pseudomonas aeruginosa is the pathogen most commonly associated with morbidity and mortality in cystic fibrosis (CF) patients. The host-pathogen interactions responsible for progressive CF lung diseases are complex. However, there is growing interest in the role of hypermutable P. aeruginosa (that is, those strains with an increased mutation frequency due to mutations in mismatch repair and error prevention genes), in terms of both bacterial adaptation and antimicrobial resistance. The prevalence of hypermutable P. aeruginosa in chronic CF infection has been established, and at 37 % is surprisingly high. To the authors' knowledge, there are no reports of prevalence during the early stages of infection, in environmental pseudomonas, which are believed to be the primary source of infection, and in epidemic strains, which have emerged as a major challenge. The aim of this study was to establish the prevalence of hypermutable P. aeruginosa in these pseudomonas populations. The hypothesis was that hypermutability would be rare in early and in environmental P. aeruginosa but in contrast would explain the relatively recent emergence of epidemic strains. It was found that 10/100 (10 %) of early isolates were strong or weak mutators, suggesting that the CF lung is not the only factor influencing the existence of mutators in this group of patients. Two weak mutators (6 %) were found in 32 environmental isolates. Only two of 15 (13 %) epidemic P. aeruginosa strains were hypermutable, and although closer analysis revealed this issue to be complex, on the whole the data suggested that the atypical characteristics of these highly transmissible strains cannot solely be explained by this phenomenon. The higher than predicted prevalence of mutators in early infection, and in environmental isolates, reinforces the importance of early and aggressive treatment for P. aeruginosa infection in CF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526842     DOI: 10.1099/mic.0.2006/005082-0

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  20 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Emergence of antibiotic-resistant extremophiles (AREs).

Authors:  Prashant Gabani; Dhan Prakash; Om V Singh
Journal:  Extremophiles       Date:  2012-08-21       Impact factor: 2.395

4.  Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa.

Authors:  Irith Wiegand; Alexandra K Marr; Elena B M Breidenstein; Kristen N Schurek; Patrick Taylor; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 5.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

6.  Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation.

Authors:  A Mena; E E Smith; J L Burns; D P Speert; S M Moskowitz; J L Perez; A Oliver
Journal:  J Bacteriol       Date:  2008-10-10       Impact factor: 3.490

7.  Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities.

Authors:  Larissa Lutz; Robson Souza Leão; Alex Guerra Ferreira; Dariane Castro Pereira; Caroline Raupp; Tyrone Pitt; Elizabeth Andrade Marques; Afonso Luis Barth
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

8.  Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.

Authors:  L F Mandsberg; O Ciofu; N Kirkby; L E Christiansen; H E Poulsen; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

Review 9.  Resistance mechanisms.

Authors:  Yasemin Cag; Hulya Caskurlu; Yanyan Fan; Bin Cao; Haluk Vahaboglu
Journal:  Ann Transl Med       Date:  2016-09

10.  Genome-scale identification method applied to find cryptic aminoglycoside resistance genes in Pseudomonas aeruginosa.

Authors:  Julie M Struble; Ryan T Gill
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.